Sanofi (SNY) AI Stock Analysis

• Market Cap: $124.09B
• Dividend Yield: 4.35%
• Average Volume (3M): 3.71M
• Price to Earnings (P/E): 12.7
• Beta (1Y): 0.58
• Revenue Growth: -9.32%
• EPS Growth: 120.62%
• Country: US
• Employees: 82,878
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 0.91
• Shares Outstanding: 2,454,938,000
• 10 Day Avg. Volume: 5,252,946
• 30 Day Avg. Volume: 3,708,417
• PEG Ratio: 3.23
• Price to Book (P/B): 1.50
• Price to Sales (P/S): 2.63
• P/FCF Ratio: 19.80
• Enterprise Value/Market Cap: 1.03
• Enterprise Value/Revenue: 2.95
• Enterprise Value/Gross Profit: 4.12
• Enterprise Value/Ebitda: 13.45
• 1Y Price Target: $62.50
• Price Target Upside: 22.79% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 75 Outperform
• Price Target: $56.00 ▲(10.02% Upside)

Sanofi's overall stock score is driven by strong financial performance and positive earnings call sentiment. The attractive valuation adds to the appeal, although technical indicators suggest caution. The company's strategic acquisitions and product launches position it well for future growth.

Positive Factors

Strategic Acquisitions

The acquisition of Blueprint Medicines enhances Sanofi's portfolio in rare immunology diseases, potentially driving long-term growth and innovation in this niche market.

Product Launch Success

Successful new product launches indicate strong R&D capabilities and market acceptance, supporting sustained revenue growth and competitive positioning.

Vaccine Business Growth

Growth in the vaccine segment underscores Sanofi's robust market presence and ability to meet global health needs, contributing to stable long-term revenue streams.

Negative Factors

Negative Revenue Growth

Negative revenue growth suggests potential challenges in market expansion or product demand, which could impact long-term financial performance and market competitiveness.

Decline in Free Cash Flow

A significant decline in free cash flow may limit Sanofi's ability to invest in future growth opportunities, affecting its financial flexibility and strategic initiatives.

Antitrust Investigation

The antitrust investigation could lead to regulatory challenges and financial penalties, potentially impacting Sanofi's operations and reputation in the long term.

Sanofi Business Overview & Revenue Model

Company Description

Sanofi (SNY) is a global healthcare company headquartered in France, specializing in the research, development, manufacturing, and marketing of pharmaceutical products and vaccines. The company operates in several key sectors, including prescription pharmaceuticals, consumer healthcare, and vaccines, focusing on therapeutic areas such as diabetes, oncology, immunology, and rare diseases. Sanofi is known for its innovative drug portfolio, which includes both established medications and cutting-edge treatments, as well as a robust vaccine division that addresses public health needs worldwide.

How the Company Makes Money

Sanofi generates revenue primarily through the sale of prescription pharmaceuticals, vaccines, and consumer healthcare products. The company earns significant income from its diverse portfolio of patented drugs, which includes treatments for chronic conditions like diabetes and oncology products. Additionally, Sanofi's vaccines division is a major contributor to its revenue, providing immunizations against diseases such as influenza and meningitis. The company also engages in strategic partnerships and collaborations with other pharmaceutical and biotech firms, enhancing its research capabilities and expanding its product offerings. These collaborations often involve shared development costs and potential profits from newly developed therapies. Furthermore, Sanofi benefits from its presence in emerging markets, where rising healthcare needs and increasing access to medications contribute to growth in sales.

Sanofi Financial Statement Overview

Summary

Sanofi demonstrates financial stability with strong profitability and a solid balance sheet. The income statement shows moderate performance with stable margins, but revenue growth is slightly negative. The balance sheet is robust with low leverage, while cash flow generation shows some weakness due to a decline in free cash flow growth.

Income Statement

Sanofi's income statement shows moderate performance with a stable gross profit margin of 71% TTM. The net profit margin improved to 14.4% TTM, indicating efficient cost management. However, revenue growth is slightly negative compared to the previous year, reflecting potential challenges in market expansion. EBIT and EBITDA margins are healthy at 18.5% and 23.0% TTM, respectively.

Balance Sheet

Sanofi maintains a solid balance sheet with a debt-to-equity ratio of 0.28, reflecting low leverage and financial stability. The return on equity (ROE) is strong at 8.5% TTM, demonstrating effective use of shareholder funds. The equity ratio stands at 56.1% TTM, indicating a robust capital structure with sufficient equity backing.

Cash Flow

Sanofi's cash flow analysis reveals a decline in free cash flow growth, falling by 73% TTM, which could constrain future investments. However, the operating cash flow to net income ratio is robust at 0.56, showcasing healthy cash conversion from profits. The free cash flow to net income ratio is lower at 0.25, signaling room for improvement in cash retention.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	43.13B	44.29B	46.03B	40.30B	39.17B	37.37B
Gross Profit	30.89B	31.08B	31.80B	28.68B	26.92B	25.21B
EBITDA	9.47B	11.03B	12.00B	13.51B	11.29B	17.51B
Net Income	9.13B	5.56B	5.40B	8.37B	6.22B	12.29B
Balance Sheet
Total Assets	124.96B	132.80B	126.46B	126.72B	120.24B	114.41B
Cash, Cash Equivalents and Short-Term Investments	15.36B	7.93B	8.71B	12.74B	10.10B	13.91B
Total Debt	22.29B	17.91B	18.42B	21.21B	22.41B	23.68B
Total Liabilities	54.68B	54.94B	52.11B	51.57B	51.21B	51.16B
Stockholders Equity	70.01B	77.51B	74.04B	74.78B	68.68B	63.11B
Cash Flow
Free Cash Flow	2.09B	5.89B	8.64B	8.32B	8.48B	5.33B
Operating Cash Flow	2.09B	9.08B	10.26B	10.53B	10.52B	7.45B
Investing Cash Flow	-776.00M	-4.41B	-6.20B	-2.08B	-7.30B	3.59B
Financing Cash Flow	-592.00M	-5.76B	-8.05B	-5.82B	-7.06B	-6.49B

Sanofi Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 50.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNY, the sentiment is Positive. The current price of 50.9 is above the 20-day moving average (MA) of 47.32, above the 50-day MA of 48.21, and above the 200-day MA of 50.11, indicating a bullish trend. The MACD of 0.19 indicates Negative momentum. The RSI at 65.59 is Neutral, neither overbought nor oversold. The STOCH value of 94.06 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SNY.

Sanofi Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PFE	83 Outperform	$155.61B	14.56	12.16%	6.25%	14.72%	―
NVS	78 Outperform	$251.64B	19.04	32.82%	3.02%	12.38%	-12.67%
MRK	76 Outperform	$222.78B	13.75	35.44%	3.63%	2.00%	20.01%
SNY	75 Outperform	$124.09B	12.66	8.39%	4.35%	-9.32%	120.62%
BMY	68 Neutral	$92.51B	18.34	29.31%	5.46%	2.57%	―
GILD	68 Neutral	$139.83B	22.42	33.26%	2.79%	3.69%	501.26%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Sanofi Corporate Events

Sanofi’s SAR446268 Gains Fast Track Designation and Boosts Biotech Investments

In September 2025, Sanofi announced that its gene therapy SAR446268 received fast track designation from the US FDA for treating non-congenital myotonic dystrophy type 1, a rare genetic disorder with no approved treatments. This designation aims to expedite the development of SAR446268, which uses RNA interference to target the DMPK gene, potentially addressing key symptoms of the disease. Additionally, Sanofi committed an additional $625 million to Sanofi Ventures to boost investments in biotech and digital health innovation, reinforcing its strategic focus on advancing healthcare solutions.

Sanofi’s Dupixent Advances in EU with Positive CHMP Opinion

On September 22, 2025, Sanofi and Regeneron announced that their drug Dupixent received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents. If approved, Dupixent would be the first targeted medicine for CSU in the EU in over a decade. This advancement could enhance Sanofi’s market position in the EU and provide new treatment options for patients with CSU who have inadequate responses to existing therapies.

Sanofi’s Tzield Gains Approval in China for Type 1 Diabetes

In September 2025, Sanofi announced significant advancements in their product offerings. On September 10, 2025, Tzield was approved in China as the first disease-modifying therapy for stage 2 type 1 diabetes, marking a new era in diabetes care by delaying the onset of stage 3 T1D. This approval aligns with Chinese guidelines emphasizing the protection of beta-cell function. Additionally, on September 11, 2025, Sanofi’s SAR402663 received fast track designation in the US for treating neovascular age-related macular degeneration, enhancing their position in the ophthalmology sector. Furthermore, on September 17, 2025, Sanofi reported positive phase 2a study results for brivekimig in treating hidradenitis suppurativa, underscoring their commitment to addressing unmet medical needs.

Sanofi’s Amlitelimab Shows Promising Results in Atopic Dermatitis Study

On September 4, 2025, Sanofi announced positive results from its COAST 1 phase 3 study, revealing that amlitelimab met all primary and key secondary endpoints in treating moderate-to-severe atopic dermatitis. Amlitelimab, a monoclonal antibody targeting OX40-ligand, showed significant efficacy in skin clearance and disease severity, with potential for dosing only four times a year. These findings highlight amlitelimab’s promise as a differentiated treatment option, supporting Sanofi’s ambition to advance in the atopic dermatitis market.

Sanofi’s Wayrilz Gains FDA Approval as First BTK Inhibitor for ITP

On August 29, 2025, Sanofi announced that the US FDA approved Wayrilz (rilzabrutinib) as the first Bruton’s tyrosine kinase (BTK) inhibitor for adults with persistent or chronic immune thrombocytopenia (ITP) who have not responded to previous treatments. This approval, based on the LUNA 3 phase 3 study, highlights Wayrilz’s potential to improve platelet counts and quality of life for over 25,000 US adults with ITP. The approval underscores Sanofi’s expertise in rare and immunological diseases, potentially positioning Wayrilz as a treatment of choice for ITP, enhancing Sanofi’s market presence in the field of rare blood disorders.

Sanofi’s Rilzabrutinib Gains EU Orphan Designation for IgG4-Related Disease

On August 14, 2025, Sanofi announced that its investigational drug rilzabrutinib received orphan designation from the European Medicines Agency for treating IgG4-related disease, a rare immune-mediated condition. This designation highlights Sanofi’s commitment to advancing treatments for rare diseases. The drug, which showed positive results in a Phase 2 study, is also under regulatory review in the US, EU, and China for immune thrombocytopenia, with a US FDA decision expected by August 29, 2025.

Sanofi Finalizes Acquisition of Vigil Neuroscience to Boost Neurology Pipeline

On August 6, 2025, Sanofi completed its acquisition of Vigil Neuroscience, Inc., enhancing its early-stage neurology pipeline with VG-3927, a novel TREM2 agonist aimed at treating Alzheimer’s disease. This acquisition, valued at approximately $470 million, is not expected to impact Sanofi’s financial guidance for 2025 and marks a strategic move to strengthen its research in neurodegenerative diseases.

Sanofi Releases 2025 Half-Year Financial Report

In July 2025, Sanofi released its half-year financial statements and management report, highlighting a decrease in total assets from €132,798 million in December 2024 to €124,959 million in June 2025. This financial update may impact Sanofi’s market positioning and stakeholder confidence, as it reflects changes in the company’s asset management and financial health over the first half of the year.

Sanofi Reports Strong Q2 2025 Performance with Revised Sales Guidance

In July 2025, Sanofi reported a strong performance for the second quarter, with a 10.1% increase in sales at constant exchange rates and a solid growth in business earnings per share (EPS). The company’s pharmaceutical launches, particularly ALTUVIIIO, and the COPD launch of Dupixent significantly contributed to this growth. Sanofi also made progress in its pipeline with several regulatory approvals and acquisitions, including Blueprint in rare diseases. The company has revised its 2025 sales guidance to high single-digit growth, reflecting confidence in its strategic direction and continued focus on R&D and innovation.

Sanofi Advances Multiple Myeloma Treatments with EU Approval and US Orphan Drug Designation

In July 2025, Sanofi announced two significant developments in its multiple myeloma treatment portfolio. On July 25, 2025, the European Commission approved Sarclisa in combination with VRd for the treatment of transplant-eligible newly diagnosed multiple myeloma patients, based on positive results from the GMMG-HD7 phase 3 study. This approval marks Sarclisa’s availability in the EU across all lines of therapy for multiple myeloma. Additionally, on July 30, 2025, Sanofi’s SAR446523, a GPRC5D monoclonal antibody, received orphan drug designation in the US for multiple myeloma, highlighting the company’s commitment to addressing unmet needs in cancer care.

Sanofi’s SAR446597 Gains Fast Track Status and Vicebio Acquisition Announced

In July 2025, Sanofi announced that its SAR446597 therapy received fast track designation from the US FDA for treating geographic atrophy due to age-related macular degeneration, highlighting its potential to address unmet medical needs in retinal diseases. Additionally, Sanofi revealed plans to acquire Vicebio, aiming to expand its respiratory vaccines pipeline, which could enhance its market position and offer new growth opportunities.

Sanofi Finalizes Acquisition of Blueprint Medicines

On July 18, 2025, Sanofi completed its acquisition of Blueprint Medicines Corporation, enhancing its portfolio with a commercialized medicine and a promising pipeline in systemic mastocytosis and other KIT-driven diseases. This acquisition strengthens Sanofi’s presence among allergists, dermatologists, and immunologists, and is expected to advance its immunology pipeline. The transaction, financed through cash and commercial paper issuances, is immediately accretive to gross margin and will positively impact business operating income and EPS after 2026. Blueprint’s shares will no longer be traded on NASDAQ following the merger.

Sanofi’s Riliprubart Gains Orphan Drug Status in US and Japan

In June 2025, Sanofi announced that its investigational drug riliprubart received orphan drug designation from the US FDA for treating antibody-mediated rejection in solid organ transplantation, highlighting a significant unmet need in transplant medicine. Additionally, riliprubart was granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy, reinforcing Sanofi’s commitment to addressing rare diseases and enhancing its position in the biopharmaceutical industry.